The drug maker Sanofi Pasteur is getting into the race to develop a vaccine to guard towards the brand new coronavirus sweeping via China, the corporate introduced Monday.
David Loew, Sanofi’s international head of vaccines, introduced the corporate would associate with the U.S. Biomedical Superior Analysis and Growth Authority—referred to as BARDA—to make a vaccine utilizing the corporate’s recombinant DNA platform.
Loew mentioned the corporate’s earlier work to develop a vaccine for SARS—a cousin virus—provides it a leg up on this work.
“Addressing a worldwide well being risk similar to this latest coronavirus goes to take a collaborative effort, which is why we’re working with BARDA to rapidly advance a possible vaccine candidate,” mentioned Loew.
“Whereas we’re lending our experience the place doable, we consider the collaboration with BARDA might present probably the most significant leads to defending the general public from this newest outbreak,” he mentioned.
Loew mentioned the corporate expects to have a vaccine candidate—a prototype—to check in vitro inside six months and may very well be prepared to check the vaccine in folks inside a 12 months or 18 months.
Loew famous the DNA recombinant platform is already used to make flu vaccine licensed within the U.S., which suggests regulators are accustomed to it. Sanofi additionally has large-scale manufacturing capability for a majority of these vaccines.
Sanofi is the second main vaccine maker to announce it can attempt to make a vaccine towards the brand new virus, which has contaminated over 70,000…